|
FI102355B1
(fi)
|
1988-02-11 |
1998-11-30 |
Bristol Myers Squibb Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5977316A
(en)
|
1995-01-17 |
1999-11-02 |
The Board Of Trustees Of The University Of Kentucky |
Monoclonal antibody 1A7 and related polypeptides
|
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
KR20030031957A
(ko)
|
2000-07-12 |
2003-04-23 |
아이덱 파마슈티칼즈 코포레이션 |
Ｂ 세포 고갈 항체 및 면역 조절 항체 관련 적용의 조합을이용한 ｂ 세포 악성종양의 치료
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
CN100574803C
(zh)
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在治疗肿瘤性疾病中的用途
|
|
AU2002237972B2
(en)
|
2001-01-31 |
2007-11-29 |
Biogen Idec Inc. |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
WO2003040187A1
(en)
|
2001-11-08 |
2003-05-15 |
Yang Sheng Tang Company Limited |
Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
|
|
DE60230918D1
(de)
|
2001-11-16 |
2009-03-05 |
Biogen Idec Inc |
Polycistronische expression von antikörpern in cho zellen
|
|
CA2505717A1
(en)
|
2002-11-15 |
2004-06-03 |
Immunomedics, Inc. |
Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
|
|
JP4959136B2
(ja)
|
2002-12-13 |
2012-06-20 |
イミューノメディクス、インコーポレイテッド |
細胞内で開裂可能な結合を有する免疫接合体
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
KR101351122B1
(ko)
|
2003-05-09 |
2014-01-14 |
듀크 유니버시티 |
Ｃｄ２０-특이적 항체 및 이를 이용한 방법
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
US7241598B2
(en)
|
2004-06-29 |
2007-07-10 |
The Chinese University Of Hong Kong |
Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
|
|
US7371825B2
(en)
*
|
2004-06-30 |
2008-05-13 |
Centocor, Inc. |
Anti-MCP-1 antibodies, compositions, methods and uses
|
|
AU2006203889A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
CRIPTO binding molecules
|
|
JP5837730B2
(ja)
|
2005-02-10 |
2015-12-24 |
ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
抗インターフェロンアルファモノクローナル抗体及び使用方法
|
|
US8318906B2
(en)
|
2005-04-15 |
2012-11-27 |
The Regents Of The University Of California |
EMP2 antibodies and their therapeutic uses
|
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
|
ZA200709956B
(en)
|
2005-05-20 |
2009-02-25 |
Genentech Inc |
Pretreatment of a biological sample from an autoimmune disease subject
|
|
WO2006133450A2
(en)
|
2005-06-08 |
2006-12-14 |
Duke University |
Anti-cd19 antibody therapy for the transplantation
|
|
EP2295080A3
(en)
|
2005-07-25 |
2011-06-22 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
WO2007140371A2
(en)
|
2006-05-30 |
2007-12-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
AU2007282023B2
(en)
|
2006-08-03 |
2012-09-13 |
Vaccinex, Inc. |
Anti-IL-6 monoclonal antibodies and uses thereof
|
|
CA2663536A1
(en)
|
2006-10-24 |
2008-05-02 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
SG10201808730VA
(en)
|
2007-04-03 |
2018-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific binding domain
|
|
CN101990439A
(zh)
|
2007-07-06 |
2011-03-23 |
特鲁比昂药品公司 |
具有置于c末端的特异性结合结构域的结合肽
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
GB2454915B
(en)
|
2007-11-23 |
2012-02-15 |
Schlumberger Holdings |
Spooling apparatus for well intervention system
|
|
WO2009085576A2
(en)
|
2007-12-28 |
2009-07-09 |
Spring Bioscience Corporation |
Positive control cell pellets for immunohistochemistry and methods of use thereof
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
US7740844B2
(en)
|
2008-04-29 |
2010-06-22 |
Taiwan Liposome Co. Ltd |
Anti-VEGF monoclonal antibody
|
|
EP2281006B1
(en)
|
2008-04-30 |
2017-08-02 |
Immunogen, Inc. |
Cross-linkers and their uses
|
|
JP2011524421A
(ja)
|
2008-06-16 |
2011-09-01 |
イミュノジェン・インコーポレーテッド |
新規の相乗効果
|
|
WO2010009124A2
(en)
|
2008-07-15 |
2010-01-21 |
Genentech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
|
WO2010057047A1
(en)
|
2008-11-13 |
2010-05-20 |
Trubion Pharmaceutics, Inc. |
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
JP2013506709A
(ja)
|
2009-10-06 |
2013-02-28 |
イミュノジェン・インコーポレーテッド |
有効なコンジュゲートおよび親水性リンカー
|
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
|
US9173961B2
(en)
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
|
AR080155A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos anti-cd20 y su utilizacion
|
|
MX338932B
(es)
|
2010-03-12 |
2016-05-06 |
Immunogen Inc |
Moleculas de union cd37 y sus inmunoconjugados.
|
|
AU2011239583A1
(en)
|
2010-04-15 |
2012-11-29 |
Alper Biotech, Llc |
Monoclonal antibodies against HER2 antigens, and uses therefor
|
|
TR201902180T4
(tr)
|
2011-03-29 |
2019-03-21 |
Immunogen Inc |
Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
|
|
CN105999293B
(zh)
|
2011-04-01 |
2019-07-23 |
德彪发姆国际有限公司 |
Cd37结合分子及其免疫缀合物
|
|
US20130058947A1
(en)
*
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
KR20140103140A
(ko)
*
|
2011-12-13 |
2014-08-25 |
노르딕 나노벡터 에이에스 |
치료용 키메릭 항-cd37 항체 hh1
|
|
RU2014140119A
(ru)
*
|
2012-03-30 |
2016-05-27 |
Иммьюноджен, Инк. |
Способы повышения эффективности терапии на основе cd37
|
|
JP2015517512A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体の更なる薬剤との併用
|
|
US20140120083A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
AU2013360335B2
(en)
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
WO2014143807A2
(en)
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|
|
BR112015030457A2
(pt)
|
2013-06-07 |
2017-08-22 |
Nordic Nanovector As |
Método para regular positivamente a expressão de antígeno
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
JP6478989B2
(ja)
|
2013-11-07 |
2019-03-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
|
|
WO2015116729A2
(en)
*
|
2014-01-28 |
2015-08-06 |
Emergent Product Development Seattle, Llc |
Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
|
|
WO2015175533A2
(en)
|
2014-05-13 |
2015-11-19 |
Immunogen, Inc. |
Anti-cd37 immunoconjugate dosing regimens
|
|
UA125496C2
(uk)
|
2015-06-08 |
2022-04-13 |
Дебіофарм Інтернаціонал, С.А. |
Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
|
|
AU2016316758B2
(en)
|
2015-08-28 |
2023-02-02 |
Debiopharm International, S.A. |
Antibodies and assays for detection of CD37
|
|
WO2018083633A1
(en)
|
2016-11-02 |
2018-05-11 |
Debiopharm International, S.A. |
Methods for improving anti-cd37 immunoconjugate therapy
|
|
CA3101790A1
(en)
|
2018-05-30 |
2019-12-05 |
Debiopharm International, S.A. |
Anti-cd37 immunoconjugate dosing regimens
|